NASDAQ:SKYE Skye Bioscience (SKYE) Stock Price, News & Analysis $5.84 -0.22 (-3.63%) (As of 09/6/2024 08:49 PM ET) Add Compare Share Share Today's Range$5.71▼$6.1050-Day Range$4.15▼$6.8652-Week Range$1.44▼$19.41Volume133,700 shsAverage Volume122,919 shsMarket Capitalization$163.92 millionP/E RatioN/ADividend YieldN/APrice Target$19.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Skye Bioscience alerts: Email Address Skye Bioscience MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside229.6% Upside$19.25 Price TargetShort InterestBearish7.72% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.30Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.06) to ($1.21) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.48 out of 5 starsMedical Sector861st out of 910 stocksPharmaceutical Preparations Industry402nd out of 426 stocks 3.5 Analyst's Opinion Consensus RatingSkye Bioscience has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageSkye Bioscience has only been the subject of 2 research reports in the past 90 days.Read more about Skye Bioscience's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.72% of the float of Skye Bioscience has been sold short.Short Interest Ratio / Days to CoverSkye Bioscience has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in Skye Bioscience has recently increased by 3.96%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldSkye Bioscience does not currently pay a dividend.Dividend GrowthSkye Bioscience does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SKYE. Previous Next 0.9 News and Social Media Coverage News SentimentSkye Bioscience has a news sentiment score of -0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Skye Bioscience this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for SKYE on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Skye Bioscience to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Skye Bioscience insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.73% of the stock of Skye Bioscience is held by insiders.Percentage Held by InstitutionsOnly 21.09% of the stock of Skye Bioscience is held by institutions.Read more about Skye Bioscience's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Skye Bioscience are expected to decrease in the coming year, from ($1.06) to ($1.21) per share.Price to Book Value per Share RatioSkye Bioscience has a P/B Ratio of 2.43. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Skye Bioscience's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S. housing… it's in artificial intelligence. And unless you know what’s really going on in this sector, you could be wiped out. You see, while there is no doubt that the recent advancements in artificial intelligence are game-changing and will drive colossal innovation in every sector of the economy... There's also no escaping that The Big AI Die-Up is coming.So go here now to read my new report The Big AI Die-Up… while you still can. About Skye Bioscience Stock (NASDAQ:SKYE)Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.Read More SKYE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SKYE Stock News HeadlinesSeptember 7 at 12:56 AM | markets.businessinsider.comCantor Fitzgerald Reaffirms Their Buy Rating on Skye Bioscience (SKYE)September 4 at 5:22 PM | seekingalpha.comSkye: Moving Weight Loss Drugs To The Next LevelSeptember 7, 2024 | Golden Crest (Ad)Biden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.September 3, 2024 | markets.businessinsider.comSkye Bioscience Appoints Puneet Arora As New Chief Medical OfficerSeptember 3, 2024 | finance.yahoo.comSkye Bioscience Appoints Puneet S. Arora, MD, as Chief Medical OfficerAugust 29, 2024 | americanbankingnews.comSkye Bioscience (NASDAQ:SKYE) Earns "Overweight" Rating from Cantor FitzgeraldAugust 29, 2024 | americanbankingnews.comSkye Bioscience (NASDAQ:SKYE) Rating Reiterated by Cantor FitzgeraldAugust 28, 2024 | investing.comSkye Bioscience shares hold Buy ratingSeptember 7, 2024 | Golden Crest (Ad)Biden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.August 26, 2024 | markets.businessinsider.comCraig-Hallum Keeps Their Buy Rating on Skye Bioscience (SKYE)August 26, 2024 | globenewswire.comSkye Bioscience to Participate in Upcoming Healthcare Investment ConferencesAugust 24, 2024 | finanznachrichten.deSkye Bioscience, Inc.: Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)August 23, 2024 | globenewswire.comSkye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)August 22, 2024 | globenewswire.comSkye Bioscience Launches Phase 2 CBeyond Clinical Trial of its Differentiated CB1 Inhibitor, Nimacimab, in Patients with ObesityAugust 19, 2024 | globenewswire.comSkye Bioscience, Inc. (SKYE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsAugust 15, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Skye Bioscience (SKYE), Urogen Pharma (URGN)August 13, 2024 | globenewswire.comSkye Bioscience, Inc. (SKYE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsAugust 11, 2024 | msn.comCo-founder of Smartmatic voting machine company charged with paying bribes for Philippine contractsSee More Headlines Receive SKYE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Skye Bioscience and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/09/2024Today9/07/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SKYE Previous SymbolNASDAQ:SKYE CUSIPN/A CIK1516551 Webskyebioscience.com Phone858-410-0266FaxN/AEmployees11Year FoundedN/APrice Target and Rating Average Stock Price Target$19.25 High Stock Price Target$25.00 Low Stock Price Target$14.00 Potential Upside/Downside+229.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-37,650,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-111.83% Return on Assets-80.69% Debt Debt-to-Equity RatioN/A Current Ratio6.07 Quick Ratio6.07 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.40 per share Price / Book2.43Miscellaneous Outstanding Shares28,068,000Free Float27,863,000Market Cap$163.92 million OptionableOptionable Beta1.81 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Punit S. Dhillon B.A. (Age 44)Executive Chairman, President, CEO & Secretary Comp: $720kDr. Christopher G. Twitty Ph.D. (Age 51)Chief Scientific Officer Mr. Tu Diep M.Sc. (Age 43)Chief Development Officer Key CompetitorsApplied TherapeuticsNASDAQ:APLTReplimune GroupNASDAQ:REPLHumacyteNASDAQ:HUMAWave Life SciencesNASDAQ:WVEORIC PharmaceuticalsNASDAQ:ORICView All CompetitorsInstitutional OwnershipPoint72 Asset Management L.P.Bought 560,000 shares on 8/19/2024Ownership: 1.995%Driehaus Capital Management LLCBought 650,758 shares on 8/16/2024Ownership: 2.319%Perceptive Advisors LLCBought 500,000 shares on 8/16/2024Ownership: 1.781%CVI Holdings LLCBought 679,739 shares on 8/15/2024Ownership: 2.422%Point72 Asia Singapore Pte. Ltd.Bought 27,768 shares on 8/15/2024Ownership: 0.099%View All Institutional Transactions SKYE Stock Analysis - Frequently Asked Questions How have SKYE shares performed this year? Skye Bioscience's stock was trading at $2.72 at the beginning of the year. Since then, SKYE shares have increased by 114.7% and is now trading at $5.84. View the best growth stocks for 2024 here. How were Skye Bioscience's earnings last quarter? Skye Bioscience, Inc. (NASDAQ:SKYE) issued its quarterly earnings data on Friday, August, 9th. The company reported ($0.20) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.20). Who are Skye Bioscience's major shareholders? Top institutional investors of Skye Bioscience include Logos Global Management LP (4.64%), CVI Holdings LLC (2.42%), Driehaus Capital Management LLC (2.32%) and Point72 Asset Management L.P. (2.00%). How do I buy shares of Skye Bioscience? Shares of SKYE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SKYE) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Skye Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Skye Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
